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is associated with residual vascular risk, beta-cell
function loss and microangiopathy in type 2
diabetes females
Michel P Hermans1*, Sylvie A Ahn2 and Michel F Rousseau2Abstract
Background: Atherogenic dyslipidemia (AD), defined as low HDL-C plus elevated triglycerides (TG), comorbid to
T2DM, increases cardiometabolic risk for CAD even when LDL-C is at target. In T2DM males, AD was shown to
correlate with β-cell function loss, yet it is not established whether this applies across gender.
Aim: To establish the prevalence and severity of AD in T2DM females, and to determine how it relates to
cardiometabolic phenotype, glucose homeostasis, micro- and macrovascular complications, and 10-year absolute
CV risk (UKPDS Risk Engine).
Methods: 340 T2DM females were ranked according to quintiles (Q) of the continuous variable log(TG)/HDL-C, with
AD prevalence defined as HDL-C <50 mg.dL-1 plus TG ≥150 mg.dL-1, and β-cell function assessed with HOMA.
Results: AD prevalence was 35%; mean HDL-C and TG were 52 (15) and 160 (105) mg.dL-1. AD was significantly
related to central fat, metabolic syndrome, sedentarity and skeletal sarcopenia, as well as to hsCRP, fibrinogen, uric
acid, cystatin-C, Big ET-1, and 10-year UKPDS CV risk. AD correlated stepwise with lower β-cell function and
hyperbolic product, and with accelerated loss of residual insulin secretion, higher HbA1c and prevalent
microangiopathy.
Conclusions: log(TG)/HDL-C is a simple means to grade AD and residual macrovascular risk in T2DM females. This
ratio associates with major non-LDL cardiometabolic variables and ranks predicted CAD risk. In addition, log(TG)/
HDL-C identifies worsening glucose homeostasis, poorer glycemic control, and prevalent microangiopathy.
Keywords: HDL-C, Triglycerides, Cardiovascular risk, Microangiopathy, β-cell function, Hyperbolic product, Gender,
DiabetesIntroduction
Current guidelines recommend intensive lowering of low-
density lipoprotein cholesterol (LDL-C) in type 2 diabetes
mellitus (T2DM) patients [1-5]. The common form of
T2DM, associated with insulin resistance (IR) and the
metabolic syndrome (MetS) is characterized by a singular,
non-LDL dyslipidemia, defined as atherogenic dyslipide-
mia (AD). The hallmark of AD is decreased levels of high-* Correspondence: michel.hermans@diab.ucl.ac.be
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reproduction in any medium, provided the ordensity lipoprotein cholesterol (HDL-C) together with
raised triglycerides (TG). AD substantially contributes to
residual vascular risk (RVR), even when LDL-C is at or
below targets, both in diabetic and nondiabetic popula-
tions. The presence and/or severity of AD can be estab-
lished either from the combined occurrence of high TG
levels and low HDL-C or from the ratio of fasting TG to
fasting HDL-C, with prior log transformation of TG levels
allowing to compute a broad range of TG values [2-11].
Whereas screening for AD provides clinically relevant in-
formation for assessing RVR, it is rarely performed due to
lack of agreement or consensual cut-offs to define/gradeal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lowering therapies (LLD).
We previously reported that log(TG)/HDL-C is a use-
ful measure of increased cardiometabolic risk in T2DM
males, in whom the ratio also relates to poorer meta-
bolic control and β-cell function loss [7]. In diabetic
females, there exists a reversed dichotomy in risk factors
for CAD vis-à-vis nondiabetic women, the former no
longer benefiting from female gender’s risk protection.
Thus, diabetic women have more severe dyslipidemia,
more prevalent obesity and abdominal fat, higher sub-
clinical inflammatory markers, more severe/prevalent
hypertension or MetS. Worryingly, diabetic women are
less often at targets for major modifiable micro- and
macrovascular risk factors, leaving them exposed to
higher RVR than males [12-15]. The aim of the present
study was (i) to establish and grade AD prevalence in a
cohort of T2DM females using the continuous variable
log(TG)/HDL-C; (ii) to determine whether this ratio
relates to their cardiometabolic phenotype or glucose
homeostasis determinants; and (iii) to assess the associ-
ation between AD and micro- or macrovascular compli-
cations, and its impact on absolute 10-year CV risk from
the United Kingdom Prospective Diabetes Study (UKPDS)
calculator [16].
Methods
This cross-sectional study included 340 female T2DM
outpatients, attending the Diabetes Clinic between Janu-
ary 2008 and June 2011. Patients were divided according
to quintiles (Q) of baseline, pre-LLD log(TG)/HDL-C
values. The following variables were recorded: age, eth-
nicity, attained educational level (dichotomised as low
vs. high, based on higher achieved education degree [no
education, primary or secondary vs. higher education
and university]), known diabetes duration, family history
(CVD, diabetes mellitus), self-reported leisure-time (LT)
weekly exercise duration, and daily-time spent watching
screen(s) (television, computers and/or visual numeric
media), as surrogate for LT sedentarity [7]. The pres-
ence of a MetS (score ≥3/5) was defined according to
the joint harmonized IDF/NHLBI/AHA/WHF/IAS/IASO
criteria [17,18].
Pre-LLD values were retrieved from patients’ records,
and used to assess AD prevalence in LLD-treated
patients; otherwise, in non-LLD-treated patients, current
lipids and AD prevalence were obtained from last avail-
able lipid values from the same specimen. In LLD-
treated patients, current lipids values were those from
last available, post-LLD lipid values. AD prevalence was
defined as the combination of MetS criteria for low
HDL-C in females (<50 mg.dL-1) and high fasting TG
(≥150 mg.dL-1 for both genders) at baseline. AD severity
was assessed from log(fasting TG)/fasting HDL-C.Normal values for log(TG)/HDL-C, from 44 healthy
white Caucasian females: 0.036 (mean); 0.034 (median);
0.014 (SD); 0.014 (min.); 0.094 (max.); 0.025 (perc. 25)
and 0.042 (perc. 75) [7].
Patients were measured for body weight, height, body
mass index (BMI), relative and total body fat (BodyFat
Analyzer, Omron BF 500), waist circumference and coni-
city index. Ultrasonographic evidence for fatty liver was
considered in the presence of hyperreflectivity in the ab-
sence of etiological factors associated with liver steatosis,
including excess ethanol intake [19-25]. Computer-based
Homeostasis Model Assessment (HOMA) of insulin sen-
sitivity and β-cell function was previously detailed
(http://www.dtu.ox.ac.uk). Values of HOMA B (%) were
plotted as a function of HOMA S (%), defining a hyper-
bolic product area (β×S) [unit: %2; normal value: 100%,
corresponding to 104 %2], which represents the true,
underlying β-cell function. (BxS) loss over a subject’s
lifetime span was obtained by dividing 100-(BxS) by sub-
jects’ age at the time of HOMA-modeling, providing an
estimate of annual (BxS) loss rate (%.year-1) [26-29].
Current use of oral antidiabetic drugs, insulin, blood
pressure (BP)-lowering drugs, aspirin, and LLD(s) was
recorded. Hypertension was defined as systolic BP ≥140
mmHg and/or diastolic BP ≥90 mmHg, or current treat-
ment with BP-lowering drug(s). Coronary artery disease
(CAD) was inferred from medical history (myocardial in-
farction, angioplasty, stenting, revascularization surgery
and/or significant coronary stenosis confirmed by angi-
ography) and systematic review of procedures, screening
(exercise testing, echocardiography) or subclinical dis-
ease imaging data in the patient’s records. Stroke was
defined according to UK Prospective Diabetes Study
(UKPDS) criteria: any neurological deficit ≥1 month,
without distinction between ischaemic, embolic and
haemorrhagic strokes. In patients with multiple CV
events, only the first one was considered for prevalence
[16]. Peripheral artery disease (PAD) was defined by a
medical history of lower-limb(s) claudication and/or
clinical or imaging evidence for ischemic diabetic foot,
angioplasty, stenting, revascularization surgery and/or
significant lower-limb artery stenosis at Doppler ultra-
sonography and/or angiography. UKPDS Risk Engine’s
10-year absolute CV risk for individuals in primary CV
prevention was based on the 10 following variables:
known T2DM duration, age, gender, ethnicity, smoking
status, chronic atrial fibrillation, HbA1c level, systolic BP,
total C and HDL-C [16].
Diabetic retinopathy (DRP) was diagnosed follow-
ing dilated fundus examination and fluoangiography
[30]. The presence of peripheral neuropathy was estab-
lished from clinical examination (knee and ankle
reflexes, Semmes-Weinstein 5.07 monofilament test)
and/or 4-limbs electromyography. Normo, micro- and
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excretion <30 (normo-), 30–299 (microalbuminuria) and
≥300 μg.mg creatinine-1 (macro-albuminuria) from first-
morning urine sample. Glomerular filtration rate (eGFR)
was estimated using the Modified Diet in Renal Disease
formula [31]. Glycated haemoglobin (HbA1c), total chol-
esterol (C), HDL-C, TG, LDL-C (from Friedewald’s for-
mula), non-HDL-C (by subtracting HDL-C from total
C), apolipoproteins (apo) A1 and B100, high-sensitivity
C-reactive protein (hsCRP), Big endothelin-1 [32], uric
acid, cystatin C, fibrinogen, leucocytes, total and free tes-
tosterone, sex-hormone-binding globulin, ferritin, liver
enzymes (aspartate aminotransferase [AST], alanine
aminotransferase [ALT], γ-glutamyl transferase [γGT]),
homocysteine, folic acid and vitamin B12 were deter-
mined by routine laboratory methods. Each patient gave
informed consent, the research was carried out in
compliance with the declaration of Helsinki, and the
protocol was approved by the local Institutional Review
Board (Commission d'Ethique Biomédicale Hospitalo-
Facultaire de l'UCL, Faculté de Médecine).
Statistical methods
Results are presented as means (± 1 standard deviation
(SD)) or proportions. The significance of differences be-
tween AD quintiles was assessed by one-way analysis of
variance for linear trend between means, and by a Chi-
squared test for trend for differences in proportions with
modified Bonferroni’s adjustment procedure to minimize
type 1 error resulting from multiple testing. Results were
considered significant or non-significant (NS) for p< or
≥0.05, respectively.
Results
Patient’s characteristics are described in Table 1. There
were 340 T2DM females in the whole cohort, 85% of
whom from Caucasian ancestry. AD prevalence was
35%. When patients were divided according to AD quin-
tiles of log(TG)/HDL-C, patients in the 2nd quintile (Q
II) had a mean log(TG)/HDL-C similar to that of con-
trol, nondiabetic subjects (see Methods), whereas
patients from the 3rd quintile (Q III) had a mean log
(TG)/HDL-C that corresponded to the 75th centile of
controls. In the whole T2DM cohort, mean age (1 SD)
and diabetes duration were 67 (13) years and 15 (10)
years, respectively, without significant trends across
quintiles (Qs). Past- or current smoking prevalence was
not different between Qs, whereas ethanol intake
showed a significant decreasing trend (p <0.0001). LT
physical activity and screen-watching daily duration were
significantly different across Qs, with increased sedentar-
ity and lesser exercise. There was a significant stepwise
decrease in the proportion of patients with higher edu-
cational level across quintiles, from 44% (QI) to 18%(QV), which nevertheless was above Bonferroni’s
adjusted level of significance. Hypertension prevalence
was 85% in the whole cohort, with increasing values
across Qs, and mean systolo-diastolic BP values 139 (21) /
78 (11) mmHg, without trends across Qs (Table 1).
Current glycemic control, inferred from the average of
last-available HbA1c, was above target (>7.0%) in the
whole group, and significantly worsened across Qs, with
a mean absolute differences of 0.84% between Q I/Q II
and Q V. The proportion of patients at HbA1c target
(33% in the whole cohort) also significantly decreased
across Qs, from 47% (Q I) to 21% (Q V; p <0.0001).
Prevalence of any microangiopathy (51% in the whole
cohort) significant increased across Qs, from 40% (Q I)
to 60% (Q V; p 0.0045). The increase in microvascular
complications prevalence across Qs remained significant
after adjustment for HbA1c (p 0.0261 [overall microan-
giopathy]; p 0.0114 [peripheral neuropathy]). When
patients were analyzed according to Qs of non-HDL-C,
there were no associations between the latter and the
frequency of microangiopathy, overall or site-specific. As
regards macroangiopathy, there was no trend for higher
prevalence across Qs of log(TG)/HDL-C: (overall preva-
lence (22%); CAD (15%); TIA/stroke (6%) and PAD
(5%). Epworth’s daytime sleepiness score and sleep ap-
noea syndrome prevalence significantly increased across
Qs, from 5 (4) and 0% (Q I) to 7 (4) and 12% (Q V;
p 0.0066 and 0.0011, respectively; Table 1).
There were highly-significant trends across Qs for pro-
gressively higher values in BMI, waist circumference, fat
mass, conicity index, waist-to-height ratio, visceral fat,
and fat-free mass index. Mean insulin sensitivity, β-cell
function, and the hyperbolic product between them
[BxS] were lower than the normal (100%) value in the
whole cohort: 57% (HOMA S), 65% (HOMA B), and
28.6% [BxS], respectively. There were stepwise decreases
across Qs in HOMA S and [BxS], from 82% (HOMA S)
and 35.9% [BxS] (Q I) to 39% (HOMA S) and 22.5%
(BxS) (Q V). [BxS] loss rate significantly worsened across
Qs: 1.17 %.yr-1 (Q I) to 1.52 %.yr-1 (Q V). There was a
significant increase across Qs in fasting insulinemia: 77
(Q I) to 141 pmol.l-1 (Q V; p<0.0001). Liver steatosis fre-
quency (64% prevalent in the whole cohort) significantly
rose across Qs: 27% (Q I) to 83% (Q V; p<0.0001). A
MetS phenotype was present in 86% of the entire cohort;
there was a highly-significant stepwise rise in both MetS
prevalence and score across Qs: 59% and 2.6 (Q I) to
100% and 4.7 (Q V; both p <0.0001). The contribution of
discrete components to the MetS score for each Q
showed significant trends for higher prevalence of hyper-
tension (p 0.0181) and enlarged waist circumference
(p <0.0001; Table 2).
As regards glucose-lowering therapies, 58% of patients
were treated with metformin; 41% with a β-cell
Table 1 Patient’s characteristics
all patients Q I Q II Q III Q IV Q V P
n 340 68 68 68 68 68
log (TG).HDL-C-1 0.045 0.026 0.035 0.042 0.050 0.071 ~
age years 67 (13) 67 (13) 66 (13) 67 (13) 68 (12) 65 (14) NS
diabetes duration years 15 (10) 15 (10) 14 (9) 15 (11) 16 (9) 17 (9) NS
smoking} % 72-28 75-25 77-23 72-28 68-32 68-32 NS
ethanol U.week-1 5 (11) 9 (14) 8 (13) 5 (11) 3 (6) 2 (3) 0.0001
education % 71:29 56:44 69:31 73:27 75:25 82:18 0.0007
hypertension % 85 78 82 85 88 91 0.0181
Hb A1c % 7.87 (1.62) 7.50 (1.82) 7.50 (1.54) 7.94 (1.62) 8.06 (1.50) 8.34 (1.49) 0.0073
Hb A1c mmol.mol
-1 63 (13) 58 (14) 59 (12) 63 (13) 65 (12) 68 (12) <0.0001
microangiopathy % 51 40 45 55 58 60 0.0045
retinopathy % 30 24 27 40 31 29 NS
peripheral polyneuropathy % 25 19 16 25 41 28 0.0111
macroangiopathy % 22 16 18 28 19 26 NS
Epworth score 6 (4) 5 (4) 6 (4) 5 (3) 7 (5) 7 (4) 0.0066
pathological (>9) % 18 9 17 12 25 25 0.0066
OSAS % 6 0 1 9 7 12 0.0011
Results are expressed as means (1SD) or proportions (%) }: never vs. former/current; HbA1c:glycated haemoglobin; HDL-C: high density lipoprotein cholesterol;
OSAS: obstructive sleep apnea/hyponea syndrome; Q: quintile; TG: triglycerides; NS: not significant.
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was a significant trend for higher insulin use or higher
dosage across quintiles: 35% and 0.42 UI.day-1.kg-1 (Q I)
to 58% and 1.13 UI.day-1.kg-1 (Q V; p 0.0058 and
<0.0001, respectively). LLD(s) were given to 63% of the
whole cohort, with statin; fenofibrate and/or ezetimibeTable 2 Cardiometabolic phenotype
all patients Q I
n 340 68
body mass index kg. m-2 30.3 (6.6) 26.6 (4.9)
weight kg 78.5 (17.4) 69.4 (14.3)
waist circumference cm 100 (15) 90 (12)
fat mass % 41.0 (6.8) 38.5 (7.8)
conicity index m2.kg-1 1.32 (0.10) 1.27 (0.10)
waist. height-1 0.62 (0.10) 0.56 (0.08)
visceral fat 0-30 score 10 (3) 8 (3)
fat free mass index kg.m-2 17.8 (3.4) 17.2 (3.9)
HOMA S % 57 (42) 82 (52)
HOMA B % 65 (48) 55 (40)
HOMA product [BxS] % 28.6 (18.5) 35.9 (21.1)
[BxS] loss rate %.yr-1 1.29 (0.51) 1.17 (0.53)
fasting insulinaemia pmol.1-1 114 (72) 77 (48)
metabolic syndrome % 86 59
metabolic syndrome score 0/5 to 5/5 3.7 (1.1) 2.6 (1.0)
liver steatosis % 64 27
Results are expressed as means (1 SD) or proportions (%). HOMA S and HOMA B: in
Assessment. Q: quintile.prescribed to 51%; 19% and/or 3%. There was a signifi-
cant trend for increased fenofibrate use across Qs: 9%
(Q I) to 39% (Q V; p <0.0001). None of the patients were
treated with niacin.
Mean baseline TG values were 206 (191) mg.dL-1 in the
entire cohort. There were no significant differences acrossQ II Q III Q IV Q V P
68 68 68 68
28.9 (6.5) 31.6 (5.8) 31.2 (6.8) 33.2 (6.8) <0.0001
75.9 (17.7) 81.1 (14.5) 81.3 (17.9) 84.9 (18.3) <0.0001
99 (13) 104 (13) 103 (16) 107 (14) <0.0001
40.1 (6.7) 42.9 (5.4) 41.2 (6.7) 42.5 (6.2) 0.0006
1.32 (0.08) 1.34 (0.09) 1.34 (0.10) 1.36 (0.10) <0.0001
0.61 (0.08) 0.65 (0.09) 0.64 (0.11) 0.67 (0.09) <0.0001
9 (3) 11 (3) 11 (3) 11 (3) <0.0001
17.3 (3.3) 18.1 (2.3) 17.8 (3.5) 18.8 (3.5) 0.0377
67 (45) 46 (34) 45 (26) 39 (30) <0.0001
54 (31) 77 (63) 70 (45) 70 (53) 0.0158
30.6 (20.3) 26.8 (18.0) 25.9 (11.9) 22.5 (17.1) <0.0001
1.22 (0.47) 1.30 (0.47) 1.26 (0.29) 1.52 (0.68) 0.0008
103 (78) 126 (80) 127 (69) 141 (69) <0.0001
82 94 94 100 <0.0001
3.3 (0.9) 3.8 (0.8) 4.3 (0.9) 4.7 (0.6) <0.0001
55 76 80 83 <0.0001
sulin sensitivity and β-cell function determined from Homeostatic Model
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lipid values, mean LDL-C was 100 (36) mg.dL-1; HDL-C
52 (15) mg.dL-1; and TG 160 (105) mg.dL-1. Mean non-
HDL-C was 132 (42) mg.dL-1. There were significant
trends for increasing values across Qs in non-HDL-C,
apoB100, and apoB100.apoA1
-1 (p 0.0078, <0.0001 and
<0.0001, respectively). There were also significant trends
for decreasing values across Qs in apoA1 and in LDL size’s
surrogate [LDL-C/apoB100] (both p <0.0001). Increasing
levels across Qs were also observed for hsCRP, fibrinogen,
Big ET-1, uric acid, cystatin C, and magnesium, and for
decreasing levels in SHBG (Table 3). In the entire cohort,
mean eGFR was 76 (28) ml.min-1.1.73m-2, and albumin-
uria 85 (273) μg.mg creatinine-1, without significant differ-
ences between Qs.
In the entire cohort, 258 patients were in primary CV
prevention, and as a result eligible for UKPDS risk esti-
mation. Their mean 10-year absolute CV risk prediction
was: 13 (11) % (CAD); 10 (10) % (fatal CAD); 11 (16) %
(stroke) and 2 (3) % (fatal stroke). Figure 1 illustrates
UKPDS risk for CAD, after adjustment for inter-quintile
differences in mean age: there were significant trends forTable 3 Laboratory values
all patients Q I
n 340 68
atherogenic dyslipidemia % 35 1
pre-LLD lipids
LDL-C mg.dl-1 150 (35) 149 (25)
non-HDL-C mg.dl-1 187 (41) 172 (28)
HDL-C mg.dl-1 52 (15) 69 (17)
triglycerides mg.dl-1 206 (191) 120 (66)
current lipids
total cholesterol mg.dl-1 185 (43) 195 (35)
LDL-C mg.dl-1 100 (36) 102 (31)
non-HDL-C mg.dl-1 132 (42) 121 (33)
apoB100 mg.dl
-1 92 (27) 80 (22)
HDL-C mg.dl-1 52 (15) 74 (11)
apoA1 mg.dl-1 164 (30) 195 (24)
triglycerides mg.dl-1 160 (105) 91 (42)
apoB100.apoA1
-1 0.54 (0.19) 0.39 (0.12)
LDL-C.apoB-1 1.05 (0.30) 1.23 (0.27)
hsCRP mg.dl
-1 0.50 (0.68) 0.28 (0.38)
fibrinogen mg.dl-1 340 (78) 313 (66)
Big ET-1 pg.ml-1 6.29 (2.31) 5.55 (2.45)
uric acid mg.dl-1 5.3 (1.7) 4.8 (1.6)
cystatin C mg.1-1 0.88 (0.30) 0.75 (0.23)
magnesium mEq.dl-1 1.63 (0.20) 1.67 (0.22)
SHBG nmol.1-1 48 (33) 66 (45)
Results are expressed as means (1SD) or proportions (%). apo: apoliprotein; C: ch
sensitivity C-reactive protein; LDL: low-density lipoprotein; LLD: lipid-lowering drustepwise heightened risk across Qs: 9% (CAD) and 7%
(fatal CAD) (Q I) to 20% (CAD) and 16% (fatal CAD) (Q
V; both p <0.0001). No increasing trends across Qs were
observed for risk of stroke or lethal stroke (not
illustrated).Discussion
The main findings of the present study are fourfold.
Firstly, we observed a high prevalence of AD in T2DM
females, with 35% affected, similar to that observed in
T2DM males. Secondly, the AD ratio log(TG)/HDL-C is
an easy means to estimate IR, and was strongly related
to a cardiometabolic phenotype characterized by IR,
MetS, hyperinsulinemia, central fat accretion, sarcope-
nia, liver steatosis and sedentary lifestyle. Thirdly, this
ratio was linked to a stepwise gradient for residual risk
of future CAD. Lastly, this ratio was related to decreased
insulin secretion, β-cell function loss, poorer glycemic
control and higher frequency of microangiopathies. The
AD ratio may therefore allow to easily identifying a com-
prehensive modifiable component of non-LDL, lipid-Q II Q III Q IV Q V P
68 68 68 68
12 25 56 82 ~
159 (46) 155 (28) 152 (39) 137 (28) NS
191 (54) 193 (36) 193 (46) 187 (36) NS
54 (8) 50 (9) 46 (11) 42 (8) ~
159 (80) 205 (98) 225 (204) 317 (308) ~
185 (45) 182 (43) 181 (41) 180 (51) NS
101 (38) 104 (38) 102 (34) 90 (36) NS
126 (42) 132 (41) 137 (39) 145 (49) 0.0078
90 (26) 91 (25) 96 (26) 103 (30) <0.0001
59 (6) 50 (4) 44 (4) 35 (5) ~
164 (20) 166 (23) 152 (22) 143 (32) <0.0001
121 (55) 142 (49) 176 (73) 272 (152) ~
0.52 (0.16) 0.52 (0.14) 0.62 (0.17) 0.67 (0.22) <0.0001
1.07 (0.30) 1.08 (0.26) 1.00 (0.26) 0.86 (0.25) <0.0001
0.46 (0.90) 0.53 (0.69) 0.50 (0.48) 0.70 (0.74) 0.0082
340 (76) 334 (72) 348 (69) 365 (97) 0.0025
5.14 (1.21) 6.31 (2.53) 6.71 (1.84) 7.88 (2.46) <0.0001
4.8 (1.5) 5.6 (1.4) 5.4 (1.7) 5.8 (1.8) 0.0002
0.78 (0.28) 0.88 (0.26) 0.91 (0.28) 1.03 (0.38) <0.0001
1.71 (0.16) 1.61 (0.17) 1.64 (0.21) 1.56 (0.19) <0.0001
45 (28) 43 (23) 46 (29) 40 (30) <0.0001
olesterol; ET: endothelin; HDL: high-density lipoprotein; hsCRP: high






























Figure 1 United Kingdom Prospective Diabetes Study Risk
Engine’s 10-year absolute predicted risk of developing non-fatal
or fatal coronary artery disease (CAD; grey bars) or fatal CAD
(solid bars) in 258 T2DM females according to quintiles of log
(TG)/HDL-C ranking distribution. Within each quintile, data were
obtained from subsets of patients (in % for each quintile) in primary
cardiovascular prevention (Q I: 81%; Q II: 81%; Q III: 69%; Q IV: 78%;
and Q V: 71%). HDL-C: high-density lipoprotein cholesterol; TG:
triglycerides. Significance of differences between quintiles: both
P<0.0001 (CAD and fatal CAD).
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ing in glucose homeostasis determinants [5-7].
The hallmark of AD is decreased HDL-C level to-
gether with raised TG, with LDL-C often only margin-
ally elevated [2-5,33-40]. Computing a ratio from fasting
TG (numerator) and fasting HDL-C (denominator)
allows not only for grading AD severity as a continuous
variable, but also for incorporating the effect of
mutually-reinforcing or diverging confounders affecting
both fraction’s components and that of one variable on
the variance of the other [7]. An analysis of isolated TG
or HDL-C, both indispensable determinants to define
AD, as standard continuous variables would not be able
to incorporate a measure of AD. Using consensual MetS
cutoffs for defining decreased HDL-C and elevated TG,
we observed a high prevalence of AD in T2DM females
(more than one-third). In comparison with log(TG)/
HDL-C values from non-diabetic female controls, the
mean AD ratio in T2DM females was well above normal
values, from the fourth AD quintile onwards. This
demonstrates that >40% of this population may present
with AD of varying severity. This finding was expected,
as raised TG and low HDL-C levels are used to define
MetS phenotype, and as the latter is highly prevalent
(86%) in T2DM [17,18].
To rule out any confounding effect of LLD, we used
baseline TG and HDL-C to compute the AD ratio, prior
to anti-dyslipidemic drug(s). This proved appropriate, as
the mean difference between baseline and current TG
levels in this study averaged 46 mg.dL-1. This approach
allowed thus to precisely establishing the true, under-
lying magnitude and frequency of AD in T2DM females[5,7]. There is a known gender difference in HDL-C and
TG levels in the general population, also observed in this
diabetic sample, with T2DM females exhibiting higher
mean HDL-C and lower TG values than their T2DM
males, by an average 6 and 12 mg/dl, respectively (data
not shown) [12-14]. As for lifestyle-related confounders
of AD prevalence/severity, our data showed a significant
decreasing trend across AD quintiles for alcohol intake,
the inverse association being expected due to ethanol’s
HDL-C-raising effects. On the other hand, we observed a
trend for lower educational level. This may promote less
healthy behaviours, and result in adverse (i.e. less cardio-
protective) anthropometrics and body composition.
The AD ratio was associated, in a stepwise gradation,
with higher levels of numerous non-lipid cardiometa-
bolic markers: fasting insulinemia; hsCRP; fibrinogen; Big
ET-1; uric acid, and cystatin C. Compensatory hyperin-
sulinemia is likely to represent a major underlying driver
for both AD and for the proatherogenic changes
observed in non-LDL lipids and non-lipid CV markers.
Endothelin-1 upregulation and/or nitric oxide release
imbalance by endothelial cells is another putative path-
way linking IR to macroangiopathy. Thus, insulin sti-
mulates endothelin-1 production and action through
MAP-kinase-dependent pathways, while ET-1 induces
IR and reactive hyperinsulinemia. Such a feed-back loop
may contribute to the pathogenesis of macrovascular dis-
ease in cardiometabolic states [32]. Expectedly, SHBG
levels significantly decreased across quintiles, since IR/
portal hyperinsulinemia are associated with decreased
liver production and lower levels of this androgen trans-
porter [4,5,24,25,32,39].
Accumulating evidence links AD in T2DM not only to
residual macrovascular risk, but also to residual risk for
new-onset or progression of microangiopathy [11]. In
this study, log(TG)/HDL-C was associated with lesser re-
sidual insulin secretion, as well as with more severe
hyperbolic product (BxS) loss over time, and heralded
poorer glycemic control and earlier or more intensive
need for stepping-up glucose-lowering therapies, as we
previously reported in T2DM males [7,22,23,29,41,42].
The AD ratio was associated with predicted CAD risk
and prevalent overall microangiopathy. When patients
were analyzed according to quitiles of non-HDL-C, an-
other variable which rises alongside the severity of AD,
we found no association between the latter and the fre-
quency of microangiopathy. This, together with the in-
dependence from diabetes control comforts the
relevance of resorting to the log(TG)/HDL-C ratio to es-
timate a modifiable lipid-related component of residual
vascular risk linked to AD. Noteworthy, treatment
with fenofibrate, a PPAR-α agonist that specifically
targets AD, exerts beneficial effects on macrovascular
disease in T2DM patients with AD, but also confers
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microangiopathies [3,4,9-11].
The present study has several limitations. Firstly, as a
cross-sectional hypothesis-generating study, it does not
allow for inferring causality relationships. Secondly, as
we used routine measurement of HDL-C, without HDL
subclass assessment, we cannot discriminate between
atheroprotective vs. dysfunctional, less atheroprotective
or even atherogenic particles. As the latter often concur
with decreased HDL-C, a low HDL-C level in the ratio
may nevertheless capture to some extent these qualita-
tive defects. Finally, the population under study was
mostly of European Caucasian ancestry, and the present
findings require replication in other racial/ethnic sub-
groups. Moreover, the observed associations were docu-
mented from females patients with established T2DM,
and may not necessarily exist in newly-diagnosed T2DM
females, nor in other types of diabetes or in women with
normal glucose homeostasis [43-45].
In conclusion, log(TG)/HDL-C allows for grading AD
and estimating non-LDL-related residual vascular risk in
T2DM females. This AD ratio negatively associates with
the two major determinants of glucose homeostasis. This
means that patients with more severe AD will have
poorer metabolic control in addition to higher predicted
CAD risk. The ratio log(TG)/HDL-C appears a simple,
cheap noninvasive means to better precise gender-
specific assessment and care of the female patient with
diabetes. Identifying patients with abnormal AD ratio
should allow improving selection and follow-up of those
most at risk, more likely to benefit from available or
newer therapies targeting hypertriglyceridemia and/or
hypo-HDL-cholesterolemia.
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